会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • LARGE-SCALE SYNTHESIS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS
    • 选择性雄激素受体调节剂的大规模合成
    • WO2004062612A3
    • 2004-11-04
    • PCT/US2004000618
    • 2004-01-12
    • GTX INCSTEINER MITCHELL SCHUNG KIWONDALTON JAMESMILLER DUANE DVEVERKA KAREN A
    • STEINER MITCHELL SCHUNG KIWONDALTON JAMESMILLER DUANE DVEVERKA KAREN A
    • C07C231/12C07C235/24C07C231/00
    • C07C231/12C07C235/24
    • The present invention relates to a synthetic process for the preparation of a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, and alterations in mood and cognition; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity and endometriosis, d) treatment and/or prevention of chronic muscular wasting; e) decreasing the incidence of, halting or causing a regression of prostate cancer; f) oral androgen replacement; g) preventing and/or treating dry eye conditions; h) treatment and/or prevention of begnin prostate hyperplasia (BPH); I) inducing apoptosis in a cancer cell; j) treatment and/or prevention of cancers of female sexual organs such as breast cancer, uterine cancer and ovarian cancer; and/or other clinical therapeutic and/or diagnostic areas. The process of the present invention is suitable for large-scale preparation, since all of the steps give rise to highly pure compounds, thus avoiding complicated purification procedures which ultimately lower the yield. Thus the present invention provides methods for the synthesis of non-steroidal agonist compounds, that can be used for industrial large-scale synthesis, and that provide highly pure products in high yield.
    • 本发明涉及一种制备新型雄激素受体靶向剂(ARTA)的合成方法,其显示了雄激素受体的非甾体配体的雄激素和合成代谢活性。 这些药物定义了一种新的亚类化合物,它们是选择性雄激素受体调节剂(SARM),其可用于a)男性避孕; b)治疗多种激素相关病症,例如与衰老男性(ADAM)中的雄激素降低相关的病症,例如疲劳,抑郁症,性欲减退,性功能障碍,勃起功能障碍,性腺机能减退,骨质疏松症,脱发,贫血, 肥胖症,肌肉减少症,骨质减少症,骨质疏松症以及情绪和认知改变; c)治疗与女性雄激素降低(ADIF)有关的病症,例如性功能障碍,性欲减退,性腺机能减退,肌肉减少症,骨质减少,骨质疏松症,认知和情绪改变,抑郁症,贫血,脱发,肥胖症和子宫内膜异位症,d )治疗和/或预防慢性肌肉消瘦; e)降低前列腺癌的发病率,停止或导致其消退; f)口服雄激素替代物; g)预防和/或治疗干眼症; h)治疗和/或预防begnin前列腺增生(BPH); I)诱导癌细胞凋亡; j)治疗和/或预防女性性器官的癌症,如乳腺癌,子宫癌和卵巢癌; 和/或其他临床治疗和/或诊断领域。 本发明的方法适用于大规模制备,因为所有步骤产生高纯度化合物,因此避免了复杂的纯化程序,最终降低了收率。 因此,本发明提供了用于合成非甾体激动剂化合物的方法,其可以用于工业大规模合成,并且以高收率提供高纯度产物。
    • 3. 发明申请
    • IRREVERSIBLE SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF
    • 不可逆选择性的雄激素受体调节剂及其使用方法
    • WO03074473A2
    • 2003-09-12
    • PCT/US0303121
    • 2003-02-24
    • UNIV TENNESSEE RES CORPDALTON JAMESMILLER DUANE DCHUNG KIWONHE YALISTEINER MITCHELL SVEVERKA KAREN A
    • DALTON JAMESMILLER DUANE DCHUNG KIWONHE YALISTEINER MITCHELL SVEVERKA KAREN A
    • A61K31/16A61K31/26A61K31/275C07C261/02C07C265/12C07C331/10C07C331/28C07C233/05C07C255/50
    • A61K31/16A61K31/26A61K31/275C07C261/02C07C265/12C07C331/10C07C331/28
    • In one embodiment, this invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). The SARM compounds have unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. In one embodiment, the SARM compounds bind irreversibly to the androgen receptor. In another embodiment, the SARM compounds are androgen receptor antagonists which bind irreversibly to the androgen receptor. In another embodiment, the SARM compounds are alkylating agents. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; g) decreasing the incidence of, halting or causing a regression of prostate cancer; and/or h) inducing apoptosis in a cancer cell.
    • 在一个实施方案中,本发明提供了一类雄激素受体靶向剂(ARTA)。 这些药剂定义了一种新的化合物亚类,它们是选择性雄激素受体调节剂(SARM)。 SARM化合物对雄激素受体的非甾体配体具有意想不到的抗雄激素活性。 在一个实施方案中,SARM化合物不可逆地与雄激素受体结合。 在另一个实施方案中,SARM化合物是与雄激素受体不可逆地结合的雄激素受体拮抗剂。 在另一个实施方案中,SARM化合物是烷化剂。 SARM化合物,单独或作为组合物,可用于a)男性避孕; b)治疗各种激素相关病症,例如与老年雄性雄激素降低有关的病症(ADAM),如疲劳,抑郁,性欲降低,性功能障碍,勃起功能障碍,性腺机能减退,骨质疏松症,脱发,贫血, 肥胖,肌营养不良,骨质减少,骨质疏松症,良性前列腺增生,情绪和认知和前列腺癌的改变; c)治疗与男性雄激素降低相关的病症(ADIF),如性功能障碍,性欲降低,性腺机能减退,肌营养不良,骨质减少,骨质疏松症,认知和情绪改变,抑郁症,贫血,脱发,肥胖,子宫内膜异位症,乳腺癌 癌症,子宫癌和卵巢癌; d)治疗和/或预防急性和/或慢性肌肉消瘦病症; e)预防和/或治疗干眼症状; f)口服雄激素替代疗法; g)降低前列腺癌的发生率,停止或导致消退; 和/或h)诱导癌细胞中的细胞凋亡。
    • 4. 发明申请
    • ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF
    • 雌激素受体配体及其使用方法
    • WO2013043304A9
    • 2014-04-24
    • PCT/US2012052141
    • 2012-08-23
    • GTX INCDALTON JAMESSTEINER MITCHELL SCOSS CHRISTOPHER C
    • DALTON JAMESSTEINER MITCHELL SCOSS CHRISTOPHER C
    • A01N37/18A61K31/165
    • A61K31/137A61K31/167
    • The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate (5) cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC) and palliative treatment of prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic (10) castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels.
    • 本发明涉及通过降低男性受试者的黄体生成素(LH)或LH水平而降低睾酮水平的方法以及治疗,抑制,降低发病率,降低严重程度或抑制前列腺癌,晚期前列腺( 5)癌症,去势抗性前列腺癌(CRPC),转移性阉割抗性前列腺癌(mCRPC)和姑息治疗前列腺癌,晚期前列腺癌,去势抗性前列腺癌(CRPC)和转移性阉割抗性前列腺癌(mCRPC) 在前列腺癌,晚期前列腺癌,阉割抗性前列腺癌(CRPC)和转移性(10)抗阉割前列腺癌(mCRPC)的受试者中降低PSA水平升高和/或增加SHBG水平。 本发明的化合物尽管阉割水平继发于ADT并降低高水平或增加PSA水平,但抑制游离或总睾丸激素水平。